

Ref: EPL/CS/SE/0087/2026

Date: October 02, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Regulatory Order(s)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby submit that with respect to the ongoing litigations disclosed by Emcure Pharmaceuticals Limited ("the Company"), in the Integrated Governance Reports filed, latest being for the quarter ended June 30, 2026, the Company has received various orders from the Income-tax Department imposing an aggregate penalty of Rs. 57,73,96,732 for Financial Year 2014-15 to Financial Year 2020-21 (Assessment Year 2015-16 to Assessment Year 2021-22), as detailed in **Annexure A**.

The Company is in the process of evaluating appropriate legal remedies, including filing an appeal before the Appellate Authority.

The relevant details as required pursuant to Regulation 30 and Para B(8) of Part A of Schedule III of Listing Regulations are provided in "**Annexure A**", enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

AMRUTA
AMIT
YANGALWAR

Digitally signed by
AMRUTA AMIT
YANGALWAR
Date: 2026.10.02
20:59:30 +05'30'

Amruta Yangalwar

Company Secretary and Compliance Officer

ICSI Membership No.: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Annexure-A

Disclosure under Part A of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
1	Name of the opposing party	Deputy Commissioner of Income tax, Central Circle 2 (1)- Pune (Income-tax Department)
2	Date of initiation of the litigation / dispute	December 27, 2023
3	Status of the litigation / dispute as per last disclosure	As per the disclosure made in Integrated Governance Report filed for the quarter ended June 30, 2026.
4	Current status of the litigation / dispute	Orders received for the Financial Year 2014-15 until Financial Year 2020-21 (Assessment Year 2015-16 to Assessment Year 2021-22) imposing an aggregate penalty of Rs. 57,73,96,732/-

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251